Tuesday, October 21, 2025

The Hit, the Hurt, and the 30-Cent Gold Story Kinross Already Knows

   


Stock Talk 

Gold and silver are both off some, but still at historic highs. Gold holding above $4,000, silver easing back near $47.8 after running past $50.

Even with prices still this strong, the miners are taking a beating. KGC and HL are trading off over 10% as of this note, and it doesn’t add up. The metals didn’t break — the market did.

It’s easy to say “ignore the noise,” but when screens go red, it’s not noise to the folks feeling like bag holders while market makers, hedge funds, and manipulators shake out the retail. It’s frustration and disbelief all over again.

If any of us little people step to the sidelines in some of both, who can blame us? Still, holding KGC and HL may yet defy the sentiment of the hour or the day. The coming earnings may yet prevail — with recent gold levels, there’s a fair chance Kinross could blow out estimates, maybe coming in up to or near $0.50 a share for the quarter.


Penny Stock Corner

While most traders were watching the dip, a small note hit the Fidelity feed: Kinross exercised its warrants and boosted its stake in Relevant Gold (RGCCF). No fanfare, no hype — just a modest $2.9 million top-up and a show of quiet confidence.

Relevant trades around $0.30, a true penny stock with light volume — averaging about 38,000 shares a day. That means only small limit trades, and only for those willing to wait and speculate on what Kinross may also be seeing out there.

“Relevant Gold – Wyoming Project Portfolio” map showing 40,000+ acres

Even on a day when a hit still hurts, maybe a little prospecting may restore some hope — in a 30-cent, 40-acre gold prospect with surface gold and a little patience.





Relevant Gold – Wyoming Project Portfolio” map showing 40,000 + acres

Kinross already knows this kind of ground. It built part of its success mining the same ancient, gold-bearing formations farther north. Wyoming’s belt offers that same geology inside the U.S. — stable laws, open ground, and less competition.

Relevant controls more than 40,000 acres across several projects, with mapped shear zones and visible gold at surface. For Kinross, a small investment secures a front-row seat on a big land story. The first drill results are due early next year. It’s a waiting game, thin volume and all, but sometimes that’s where the quiet setups start.

_______

Disclosure:  Jones bought 5,000 shares of RGCCF with a limit order at $0.30 — taking the gamble alongside Kinross. The Jones Report has no affiliations or arrangements with any company mentioned here in StocksToWatch. This isn’t a pump site, just conversation about what’s out there — and what may or may not be.

__


If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Friday, October 17, 2025

Silver and Gold Still Strong — and the New Wyoming Gold Story Kinross Is Watching (Penny Stock Corner)

   


Stock Talk 

a pause, not a problem

October hasn’t broken anything. Yesterday the miners were sprinting; today they’re catching their breath. That’s what bull runs sometimes do — move, rest, then move again. Gold still above four-thousand and silver near fifty tell the real story. A little red on the screen doesn’t change that; it just shakes out some nerves.

the core rides out the pullback

Gold miners are under pressure today — Hecla (HL) and Kinross (KGC) both trading softer after yesterday’s strong run. No bad news, just the usual money shuffling around in the group. Most of the forums are calling it a buying opportunity — time will tell. With the rise in silver demand and central banks collecting gold, earnings will speak for these two miners.

Kinross and Hecla eased back after yesterday’s strength. Both are steady producers with cash flow and good ground. Holding on and waiting — earnings will settle the matter. Not sweating the zigs and zags here. We’ve been on KGC from the beginning, and this looks like a no-sweat zag — the kind we ride through, not trade out of.

quiet confidence out west – a penny stock with big land

While most traders were watching the dip, a small note hit the Fidelity feed: Kinross exercised its warrants and boosted its stake in Relevant Gold (RGCCF). No fanfare, no hype — just a modest $2.9 million top-up and a show of quiet confidence.

Relevant trades around $0.30, a true penny stock with light volume — average about 38,000 shares a day. That means only small limit trades, and only for those willing to wait and speculate on what Kinross may also be seeing out there.




Relevant Gold – Wyoming Project Portfolio” map showing 40,000 + acres]

Kinross already knows this kind of ground. It built part of its success mining the same ancient, gold-bearing formations farther north. Wyoming’s belt offers that same geology inside the U.S. — stable laws, open ground, and less competition.

Relevant controls more than 40,000 acres across several projects, with mapped shear zones and visible gold at surface. For Kinross, a small investment secures a front-row seat on a big land story. The first drill results are due early next year. It’s a waiting game, thin volume and all, but sometimes that’s where the quiet setups start.

_______

Disclosure:  Jones bought 5,000 shares of RGCCF with a limit order at $0.30 — taking the gamble alongside Kinross. The Jones Report has no affiliations or arrangements with any company mentioned here in StocksToWatch. This isn’t a pump site, just conversation about what’s out there — and what may or may not be.

__


If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Thursday, October 16, 2025

Gold and Silver - And others too

   


Market Talk 

After the great day of peace in the Middle East, old hatreds stirred by Hamas continue to cause backlash among their own people of Muslim faith. The fight to disarm those who refuse to quit may yet drag on.

Meanwhile, Washington continues the shutdown as polarized parties dig in. Still, the markets chug ahead, watching for rate cuts and the next wave of revenue and earnings signals to chart the future of share prices.

Stock Talk 

Gold and silver remain the mainstay in this economic climate — real stores of value in a paper-heavy world. The two miners, Kinross (KGC) and Hecla (HL), continue to hold their ground as dependable plays amid shifting rates and global uncertainty.

Why these miners? Both Kinross and Hecla offer more than metal — they offer leverage to price, manageable costs, and production rooted in safe, stable jurisdictions. KGC’s gold output remains strong, giving it leverage when prices rise, while HL’s low-cost silver production, the largest silver miner in America, makes it a natural hedge as industrial demand climbs with AI and clean-energy expansion. In a market full of promises, these two still deliver ounces, cash flow, and earnings growth.

At the same time, other stocks may offer real opportunity as well as risk in this new AI-driven world — one built on expanding data centers, rising power demand, and the growing need for a strong defense of America and the free world.

For example, Hewlett Packard (HPE) guided lower revenues even as it aims to grow deeper into the data-center buildout. They’re talking dividend hikes and buybacks, but a downturn is still a downturn — and if you’ve been driving with some HPE, it might be time to pull over and check the gauges.

Meanwhile, Ramaco Resources (METC) has shown how rough the ride can get. Yesterday’s METC downturn whipsaw looks and feels like classic volatility — yet beneath the chop lies real promise. Their Brook Mine in Wyoming holds vast acres rich in rare earth elements (REEs), a potential key to fulfilling the nation’s critical need for domestic REE supply.

The potential — along with news feeds today showing METC and METCB bouncing back with buy mentions - keeps them in the mix for both trading and investing. Maybe some and maybe not too much.

Those REEs tie directly into the backbone of the AI and defense buildout — from electric motors to guidance systems to the servers powering data centers. And yet, while the REEs are there, sandwiched between the edges of layered coal seams and easily extracted, the separation of the rare earth minerals still needs to be proven in the pilot plant now in the planning stages.

Until that proof comes, patience and positioning will test traders’ resolve. Some shares could prove an investment — but all the same, the time lag brings doubts about when, and the in-betweens create uncertainty at higher share levels. Unless the government steps in to accelerate the buildout, those share levels could be challenged.

One name catching fresh attention is Navitas Semiconductor (NVTS) — a player in high-efficiency power chips built on gallium nitride and silicon carbide. With AI data centers and electric infrastructure both hungry for faster, cooler, and cleaner power, NVTS sits right at the junction of two megatrends. The stock has seen momentum swings, but recent ties to major partners like NVIDIA have sparked renewed interest. It’s a speculative space, yet one worth watching as the next wave of power-conversion tech takes shape.

Still, KGC and HL remain the conviction go-stocks here — steady, grounded, and true to value. Others may present possibilities to trade or invest as the future plays out. Scroll back if interested in more of the stocks we continue to watch here.

__


If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Monday, October 13, 2025

Trump’s Peace Talks to Market Walks — The Jones Report on Gains and Guardrails

  


Market Talk 

Today, this Columbus Day, the world is a step closer to a hard-fought peace between Israel and the Palestinian people. It wasn’t easy — many thousands of people died. After the Oct. 7 massacre by Hamas, the Gaza Strip lies in rubble, and the remaining hostages are finally back in Israel, many dead and twenty alive. The surrounding Arab nations worked to make a deal happen that leaves Gaza to be rebuilt and offers remaining Hamas militants amnesty if they choose to accept it and live in peace. Never forget and Never again are the words President Trump passes on from our own 9/11 tragedy.
While today may be the moment to step back and rejoice — and be thankful that cool heads are now prevailing — market and stock watchers quietly contemplate the cornucopia of factors that may affect the coming economy and various stocks.
As Americans, we can be proud (and a bit relieved) that President Trump, his team, and a coalition with Israel and the Arab countries have worked to come to a day of peace in both the surrounding Arab and Israeli lands. It’s a very hopeful sign — one that may spread its vibes to other areas.

Yet here in America, many issues remain unresolved, such as the continuing government shutdown, with jobs under siege and lost. The Fed’s strategy of lowering borrowing rates seems intact for future rate cuts. Yet inflation remains sticky, and while GDP is projected to maintain levels above the recession mark, mixed signals persist about the ability of everyday Americans to keep up with the higher costs that tariffs and the ever-growing cost of living bring.

In these days, with our market watch- have seen and lived the opportunity of staying aware. We hold conviction where facts and markets call for it — and stay nimble to survive the hedge-fund jives they throw at us. When some stocks look and feel like early opportunity, we acknowledge the speculative nature — apart from fundamentals — and may trade some in or out depending on the market winds. But never “too much” on spec stocks — if any at all.

Today’s market started out buoyant and closed on optimism. One thing to note is how it ended last week — down over 800 on both the Dow and Nasdaq. The China threat of holding back critical rare-earth elements needed by industry in semiconductors, medical technology, and refined magnets used in high-end devices opens up negative repercussions in trade that both countries rely on to keep the wheels moving. The impact of how things may develop is yet to play out. Uncertainty can be a wall of worry to climb — or like an anchor yet to be lifted.


 Stock Talk


Apart from the optimism of a return to a strong America working for more peaceful resolutions, market watchers may recall that Octobers have historically seen some tumultuous times. To stay balanced, it’s worth remembering that the worst market months have carried their share of shocks — from the crash of October 1929, to Black Monday in October 1987, and the banking crisis of October 2008.

Still, optimism can be a quiet strength. As the world steadies and the Fed hints at future easing, selective investors may find opportunity in sectors that thrive on rebuilding, innovation, and stability — while others may simply choose patience and preservation. The key, as always, is perspective.

So, let’s stop and think about a few notions. If you’ve been following this Jones Report, perhaps you’re now enjoying the fruit of your own due diligence and trading decisions. Several of the Jones stock picks have had tremendous gains — even outperforming most of the fancy-pants Wall Street hedge funds.

KGC & HL — The Metals Core

The two gold and silver mining stocks, Kinross Gold Corporation (KGC) and Hecla Mining (HL), remain steadfast hold-some positions. With gold now over $4,100 an ounce and silver at $50, KGC has nearly quadrupled in value since it was first suggested here in the single digits — but take a look at how the base price of gold itself has performed in a world where fiat-currency values are diminishing, not just in America but across the globe. Central world banks want in on gold, and the real-deal value of a hard asset looks like a fair bet to hold some.

Silver, on the other hand, continues to play both sides of the field — part precious metal, part industrial workhorse. Hecla Mining (HL) stands tall as America’s largest primary silver producer, with added strength from its gold, zinc, and lead by-products that help keep costs low. As AI data centers, solar, and electric-tech expansion continue to surge, each one quietly consumes more silver — giving HL a built-in tailwind that few analysts fully price in.

While the share prices have had hurdles at each leg, conditions appear to remain strong enough to keep both as a hold-some. How anybody trades it is up to them to decide according to their own strategy. This isn’t a pump-stocks site — we watch, and we stay aware.

For long-term holders, HL and KGC together seem to offer a rare combination: historical safety in uncertain times, and leverage to the future’s demand for real, tangible value.

Ramaco Resources (METC, METCB, METCI)

While we’re talking materials in gold and silver, let’s chat about Ramaco Resources. METC, METCB, and METCI.

Metallurgical coal remains the core of their operations, but as pointed out here when METC was in the single digits, the Brook Mine in Wyoming sits on vast acreage rich in both met coal and reported rare earth elements.

The Jones Report research has uncovered some facts the general public may not be fully aware of. For example, the Brook Mine property isn’t just a coal seam — it’s layered like a geological Oreo. Acres and acres of rolling hills hold stratified regions of coal sandwiching between five to fifteen feet of rare earths. Think Oreo cookies stacked on top of each other — the met coal is the cookie, and the rare earths are the cream — fifteen feet deep, in multiple layers.

To mine this, Ramaco can readily use high-ton scooper trucks to strip the land in layers, loading the black met coal and the brown rare-earth clay into separate staging areas. It’s straightforward, efficient, and potentially transformational if processing and extraction align with the company’s plans. As a note, the ecological practice is to backfill the land to return to the rolling fields.

The potential is clear — America sorely needs a steady domestic supply of rare earths that China continues to use as a geopolitical pawn. These include critical magnetic elements such as neodymium, praseodymium, dysprosium, and terbium — the essential ingredients for high-performance magnets used in everything from EV motors and wind turbines to precision-guided defense systems.

The risk of extracting those rare earths has been mitigated by bringing on new, experienced staff like Mr. Van Wyck, yet the pilot separation plant is still unproven — and until it runs successfully, the market remains in “show-me” mode.

If the Brook Mine’s rare-earth content proves out at scale, it will be a game-changer for Ramaco. The METC is the overall coal and REE business, the METCB shares mirror progress on the rare-earth front, while METCI, with its 8.25 percent preferred dividend tagged to the $25 a share offers income for those who like yield while waiting on development news. Between the three, Ramaco covers a wide field — coal and ree cash flow (METC), rare-earth potential, and steady income. The Jones view? Maybe some, maybe none — but the story bears watching as America looks for domestic rare-earth supply lines.

Ramaco remains in the speculative-stock category, though favored on the news of the day. One clear catalyst would be if the U.S. government formally recognizes the Brook Mine development as a critical resource and backs it. Thus, METC and METCB are garnering favor in market speculation. Will it continue favorably? Holding some from our single digits may be a way — with the key word: some.

All in all, while KGC and HL are still the real-deal stocks — with maybe some of the Ramaco issues, METC and METCB — being diversified into the tech growth side may be a consideration.

As long as the market cooperates and doesn’t correct too much, Intel (INTC) and Hewlett Packard Enterprise (HPE) may see further emerging strength as Made-in-America semiconductor and data center plays. INTC remains the underdog on AI but is rebuilding from the ground up — new fabs, new chips, and a national security angle that keeps Washington involved. HPE, meanwhile, stays in the spotlight supplying the servers and infrastructure that power the expanding AI and cloud data centers. Together, they may not be the flashiest tech names, but they’re part of the backbone — steady plays in America’s quiet high-tech revival.

The Jones Report called LRCX trading in the 60s. LRCX is over double that today at 137 — you’re welcome. Play it your way — still holding some as “a long”? Ok then. LRCX remains the premier company in etching and deposition — the backbone of how all those chips are made, everywhere. Even in China. That’s a risk, sure, but with so many chips still to be built here in America, that’s a plus, puff daddies.

Let’s Talk Straight on a Few

Kratos Defense & Security Solutions (KTOS) was suggested back when it traded in the teens. Now it’s hovering around and over 100. Many of the bullish trends we observed back then still apply — and more. Their drones, radars, and test beds for the military are all lined up for big things in terms of revenues and earnings. And yet, it remains to be seen just when those numbers fully hit.

If you’re just joining the Jones Report, take this as a note of caution with KTOS. Maybe a dip would offer a good long-term buy-some entry point. But one thing — when buying into uncertainty, whatever you think may be a good buy-in, make it half that, and inch in where bulls can be turned into steers.

With the above preamble on KTOS, here’s the bottom-line view: KTOS had a nice ride to 100. Time, orders and sales, competition, and smart money management will determine the future — along with the market whims of the institutions that hold it. The Jones view: holding some KTOS for the long-haul prospects may be a way — but taking some gain off the table for opportunity or dry powder, with a wink? That’s up to you.

Other Spec Stocks — ONCY & FLY

Oncolytics Biotech (ONCY) continues to build on its immuno-oncology platform with Pelareorep, the naturally occurring reovirus therapy we’ve spotlighted before. It remains a spec hold in the biotech corner — not for the faint of heart, but for those who believe that science and persistence can one day collide with timing and partnership. In the near term, ONCY seems deal-dependent, with the new CEO brought on to make a partner or acquisition — much like the Ambrx sale to J&J. But where is it? Things take time to develop — or not. Therein lies the speculation, maybe the gamble too.

FLY (Firefly Aerospace) isn’t your typical launch company anymore. It’s evolving fast — from rockets to orbital transport, and now toward space defense. Firefly first made headlines in 2023 when it bought Spaceflight Inc., adding the capability to deliver and reposition satellites already in orbit. But the real pivot came with its 855 million dollar acquisition of SciTec — a defense-tech firm specializing in missile tracking, remote sensing, and command-and-control analytics.

That move takes Firefly into a whole new league. It positions them not just to launch rockets but to integrate intelligence and defense systems — the kind of architecture that could underpin what some call an “aircraft carrier in space” concept. Think orbital platforms equipped to deploy, defend, or neutralize threats like killer satellites or hypersonic systems.

It’s early and still highly speculative, but the Jones view is that Firefly now sits on the cusp of being more than a rocket maker — potentially a strategic defense asset in orbit. Whether it can execute on that vision remains to be seen. Maybe some, maybe none — but FLY is one to watch as the space race shifts from launch to control.

For those watching new trends, there was some chatter linking FLY to the concept of an “aircraft carrier in space.” That wasn’t far-fetched. Around the same time that the U.S. Space Force began funding early orbital-carrier demonstrations, Firefly was expanding into the same neighborhood — launching payloads, transporting assets, and now, through SciTec, building the kind of command-and-control systems that could one day make such a platform operational. So while Firefly isn’t officially building the “carrier,” its tech and partnerships may well make it the launchpad that helps bring the idea to life.

Maybe some, maybe none.

Having nice gains is one thing — keeping them is another. Account appreciation and growth are great, but preservation is equally important. When feeling bullish, like “a long,” also think cautious optimism — especially in a tax-free IRA account where trading can breathe a little.

Sometimes, when things take too long and stocks start wavering, it’s okay to stay long — but also to think about trimming, keeping a few “back burner” shares that relieve the worry of what we can’t control. The market rewards patience, but it also respects prudence. Keep the faith, stay aware, and never forget — the best traders learn to protect their gains as carefully as they earn them.

__


If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Sunday, October 5, 2025

Sunday Feature: The Complacent Cancer Empire - and How Big Phama keeps missing the Breakthrough from Nature

   


The Complacent Cancer Empire

How Big Pharma Keeps Missing the Breakthrough Sitting in Plain Sight.
– and the perils born of complacency and profit while a breakthrough from nature — and maybe Providence — gets pushed back.


Some say Providence moves in mysterious ways. Maybe this time, it’s through an ancient virus that refuses to quit — one that nature left waiting for us to recognize. When medicine gets too comfortable, progress dies quietly. But sometimes, a spark from nature lights a fire that no empire can suppress.


The Illusion of Progress


Checkpoint inhibitors (CIs) have become a hundred-billion-dollar cash cow for Big Pharma — Merck (Keytruda), Bristol Myers Squibb (Opdivo, Yervoy), Roche/Genentech (Tecentriq), AstraZeneca (Imfinzi, Imjudo), Pfizer/Merck KGaA (Bavencio), and Sanofi/Regeneron (Libtayo). They’re marketed as miracle drugs with fancy names nobody can pronounce and results even harder to find. But the truth is stark: in cold tumors like pancreatic, ovarian, and prostate, they simply do not work. And even in “hot” tumors such as lung or melanoma, more than 70 percent of patients still fail to get durable benefit.


Big Pharma keeps pushing them anyway. Why? Because the cash cow needs feeding. They spin “potential” into trials and glossy presentations while patients get little. Over time, those cash cows turned into fat pigs — bloated on profits from drugs that barely work. Big Pharma has grown complacent, slow, and comfortable — a health empire feeding on repetition, not results.


When Science Becomes a Shield


They’ll tell you they’re just “following the science” or “moving at the FDA’s pace,” but that’s the smokescreen. When there’s profit on the line, these same companies fast-track approvals in months. Yet when a natural immune spark like Pelareorep threatens to expose their limits, suddenly caution becomes the convenient shield. The system lets them hide behind regulation — a perfect cover for complacency.

When HIV was the death sentence of the ’80s and ’90s, the world moved fast. Patients protested, regulators listened, and drugmakers cooperated. Within a few years, the “cocktail” approach turned a fatal diagnosis into a manageable disease. Cancer is no less deadly — millions die each year — yet the same urgency is nowhere to be found. The system has grown comfortable, letting time slip by while people fade quietly in hospital rooms. The science to spark a new era exists, but complacency keeps it on ice.

And it’s not just checkpoint inhibitors. Even the new wave of antibody-drug conjugates (ADCs) are stuck in the same slow lane — testing themselves only against standard chemo, one cautious inch at a time. Those trials will take years, chasing small safety margins while real innovation waits on the sidelines.


A Spark from Nature


Here’s the science. Cold tumors block T cells with a defense mechanism. CIs are supposed to cut that defense, but if no T cells are there to begin with, the drug has nothing to do.

This is where Pelareorep, developed by Oncolytics Biotech (ONCY), changes the story. Originally revealed in Dr. Albert Sabin’s polio labs in the 1950s, this ancient virus — perhaps a quiet gift of nature itself, waiting to be recognized — was later found to infect and destroy cancer cells while sparing healthy ones. Pela is not just another lab-made drug — it’s a clinically adapted virus, a gift from nature, that seeks out and infects cancer cells while sparing healthy tissue. In amplified IV doses, it penetrates tumors, cracks them open, and releases antigens that wake up the body’s T fighter cells — the immune system’s front-line soldiers. These cells replicate and multiply, then fan out to hunt down and attack cancer cells wherever they find them. Pela is more than just a spark plug. This immune platform is the critical missing piece of the Trinity that people need to help beat cancer.

And the proof is already there: when Pela was combined with Merck’s Keytruda in pancreatic cancer — a cold tumor where Keytruda alone does nothing — patients saw about a 30 percent clinical benefit rate. That’s a clear signal of what happens when the spark plug is added.

ONCY is now preparing a larger, pivotal-intent trial that pairs Pelareorep with the standard pancreatic-cancer chemo backbone — gemcitabine and nab-paclitaxel (the GnP regimen) — plus a checkpoint inhibitor. The design aims for regulatory acceptance while bringing Pela’s spark directly into a real-world frontline setting. What’s especially notable is that no checkpoint-inhibitor partner has yet been named, leaving the door open for one — or more — Big Pharmas to step in. But where are they?


Merck Sits Back — For Now


Logic says Merck should be first in line. They already saw Pela lift Keytruda’s results by roughly 30 percent in a cancer where their own drug alone does nothing. Pairing Pela with Keytruda could unlock entire new indications — ovarian, pancreatic, even prostate — each worth billions. But doing so would also expose the truth: that Keytruda isn’t enough on its own. So instead of openly embracing the spark that could expand their reach, Merck sits back — at least for now — protecting the illusion of sufficiency while the opportunity — and the patients — wait.

Roche, with Tecentriq, has even more reason to move. They’ve already seen Pela in action — it was tested with Tecentriq in breast cancer and showed it could turn cold tumors hot. Yet, despite that firsthand data, Roche has stayed silent too. With Tecentriq’s market share fading and its own combination-heavy pipeline, Roche might have the most to gain by reigniting its CI franchise with Pela — but for now, it remains on the sidelines.


The Trinity Approach: Spark → Block → Smash


What would happen if a third targeted weapon — an ADC — were added to the regimen? That’s the Trinity Approach.

In this case, it isn’t the FDA holding things back — it’s Big Pharma itself, guarding its own franchises. These companies don’t need to hide behind regulation when silence works just as well. In choosing that silence, they aren’t just avoiding Pela — they’re suppressing Oncolytics Biotech (ONCY) itself, the small company holding the spark plug that could change the cancer fight.


The Waiting Game


And here’s the irony: ONCY themselves will never call this out. They can’t. A small biotech has to play nice with Big Pharma if they want a partnership or buyout. That leaves it to outside voices to point out the obvious — that Merck and others are knowingly milking cash cows that don’t hit the mark while suppressing the one piece that could truly move the needle.

And make no mistake: Oncolytics Biotech (ONCY) is not built to go it alone. Their resources are limited, which is why they’ve openly said they’re seeking a partner or strategic deal. The science is proven, but it will take a bigger player to scale it into a front-line weapon.

The other side of the coin is that if no one steps up, ONCY will keep pushing forward by themselves — years of more trials, more dilution, and more tears for patients waiting on something that already works. That’s the gamble. Do Big Pharmas keep suppressing, or does one finally seize the spark plug?

An antibody-drug conjugate (ADC) is targeted chemo — it delivers the toxic hit straight to the tumor cells without blasting the rest of the body like broad chemo does. That’s where real durable responses finally show up.

And yet, complacent Big Pharma execs would rather keep knowingly pushing their cash cows that don’t hit the mark.

Merck may not want this because it risks showing Keytruda’s limits. But other Big Pharmas could have a massive advantage by owning the spark plug:
Roche/Genentech (Tecentriq) could reignite a fading CI franchise.
AstraZeneca (Imfinzi, Imjudo) could sharpen its push in lung and GI cancers.
Pfizer/Merck KGaA (Bavencio) could finally stand out in a crowded CI market.
Bristol Myers Squibb (Opdivo, Yervoy) could fortify its lead before patent cliffs.
Johnson & Johnson — no CI of their own, but with an ADC pipeline, they could bolt Pela onto their targeted chemo agents and leapfrog the whole CI club.

Owning Pela means you can either rescue your CI franchise or supercharge your ADC portfolio. That’s not just market share. That’s hundreds of thousands of patients each year who could finally have real durable responses — to live better, longer, and stronger if Big Pharma stepped up instead of knowingly pushing cash cows that don’t hit the mark.

There should be white sharks circling by now — rivals who can smell the weakness and opportunity. The complacent empire may be bloated, but its edges are starting to bleed. The question isn’t whether they see the spark plug — it’s which one will strike first.


Stock Talk — Who Seizes the Spark Plug?

The Trinity is in plain sight. Science has it. The first company to act on it could spark the future of oncology.

And here’s the speculation: Johnson & Johnson, with its ADC arsenal but no CI of its own, may have the most to gain by stepping up on the Trinity Approach — especially with the new CEO of ONCY already having a track record inside J&J. But they wouldn’t be alone. Novartis, with its cell-therapy programs and growing ADC pipeline, could leap in. Gilead, sitting on Trodelvy but no checkpoint inhibitor, could bolt Pela onto its arsenal and suddenly have a Trinity cocktail of its own.

While Merck protects Keytruda and the rest of the CI club keeps knowingly milking cash cows that don’t hit the mark, the real question is which outsider will seize the missing piece — Oncolytics Biotech (ONCY) — and change the game.


Feature Opinion Story by Spider J. Jones


______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Tuesday, September 30, 2025

Feature Opinion Story: WHY ONCY’s Pela is the Broad Activator Platform Big Pharma Needs for Durable Results

  


Market Talk 

The possibility of a government shutdown is back on the table. In times like this, traders often rotate toward safety. Gold and silver names like KGC and HL can catch flows as havens, while perhaps speculative activity and volume in now penny stock ONCY has been picking up with its new PDAC trial plans.

Markets can get choppy in these moments, so staying nimble elsewhere may make some sense.

Stock Talk

KGC & HL – Gold and silver miners remain front and center, each with their own strengths in a world of growing demand. Back-of-the-envelope math points to the real possibility of both stocks doubling from here.

Ramaco (METC) – METC brings a combined met coal and rare earths angle. METCB tracks the rare earth progress directly, while METCI offers an 8.25% preferred dividend — a steady yield to complement the growth side.  Maybe "some" - feel like mainstays for these times.

    

Feature

One in Four Isn't enough - Why Pela Could Expand current treatments 

From polio labs to today’s trials, Pelareorep shows signs of powering treatments across cancers.

Pelareorep’s story starts not in a corporate lab, but in nature. The reovirus has circulated quietly among humans for decades, often causing no symptoms at all. Back in the 1950s, Dr. Albert Sabin, best known for developing the oral polio vaccine, noted the virus’s unusual behavior in cancer cells and claimed its discovery in that context. Decades later, scientists like Dr. Patrick Lee unlocked its potential as an oncolytic virus. Oncolytics Biotech Inc. (ONCY) has since turned it into a clinical therapy: pelareorep, a safe, IV-delivered version designed to amplify what casual reovirus exposure could never accomplish on its own — infiltrating tumors, cracking open and lysing cancer cells, and opening the door for the immune system to rush in.

Once inside, Pela sparks an immune cascade. Tumor cells break apart, antigens spill out, and T-cells begin replicating and swarming into cancers that were previously cold and invisible to the immune system. Safety has been shown across years of small trials, but more importantly, so have signals of effect: breast cancer patients in IND-213 lived longer, pancreatic patients have shown a 62% response rate including a complete response, and activity has been reported in colorectal and KRAS-mutant cancers. The evidence keeps pointing in one direction — Pela doesn’t just slip safely into patients, it leaves behind immune activation where none existed before.

ONCY Is Planning Ahead

ONCY isn’t standing still. A new PDAC registration trial is already being planned to press the advantage from years of safety data and immune activation signals.

If retail can see it, Big Pharma may be seeing it too. And perhaps one of them will seize the opportunity to take the mantle of advancing Pela — not in piecemeal, but in a bigger and broader manner, as part of the Trinity Approach.

The planned PDAC registration trial could also be the opening for Merck. Keytruda is their crown jewel, yet in pancreatic cancer it helps only a fraction of patients. Pela’s ability to wake the immune system could expand Keytruda’s reach — turning cold tumors hot. And perhaps the cleanest path would be for Merck to take over and hold ONCY as a subsidiary, bringing not just the resources to run broader trials, but also their arsenal of checkpoint inhibitors and ADCs to integrate with the immune-based Pela platform.

At present, checkpoint drugs, ADCs, and targeted plays are only pieces of the mechanism. Without the spark of immune activation, they fall short — helping only about one in four patients. Pela could be that ignition — the platform inside a broader Trinity Approach that expands their reach across cancers, potentially opening significant and durable responses for over 190,000 additional patients in the U.S. each year who today see little benefit.

Conclusion

And that’s the point. Big Pharma keeps building fancy engines for niche cases, but without the spark plug of Pela, they risk stalling — because it’s Pela that can more broadly crack open cancer cells, activate the immune system, and make tumors visible so the other expensive agents can actually work synergistically with Pela to foster more durable results. For small investors, the Jones way on spec stocks still applies — maybe some, not too much, or even none. Just enough to keep it fun.

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Wednesday, September 24, 2025

Mainstays that could well DOUBLE and a Spec stock on a Trinity note: ONCY with Merck?

 


Market Talk 

Although markets have climbed, stocks are still chopping sideways as they trade based on factors and dynamics tied to each sector and each company. But on the equity side, a few names continue to stand out.


 Stock Talk


KGC & HL – Gold and silver miners remain front and center, each with their own strengths in a world of growing demand. Back-of-the-envelope math points to the real possibility of both stocks doubling from here.

Ramaco (METC) – METC brings a combined met coal and rare earths angle. METCB tracks the rare earth progress directly, while METCI offers an 8.25% preferred dividend — a steady yield to complement the growth side.  Maybe "some" - feel like mainstays for these times.

    

Spec Stock Corner

ONCY – A different kind of story. It feels deal-dependent.  The Trinity Approach that's been missing a piece to increase the odds of surviving cancer.

https://stockstowatch.blogspot.com/2025/09/the-trinity-missing-puzzle-piece-to.html

The recent KRAS update has renewed visibility, and the Trinity Approach notion — with ONCY’s Pela as the lead immune agent — highlights why, one of several big Phama's - Merck could be the natural fit. Merck already owns the world’s top checkpoint inhibitor (CI) in Keytruda and has built a serious pipeline of antibody–drug conjugates (ADCs). Pela could slot in as the missing immune leg to strengthen their regimens — and with Merck’s infrastructure, a fast track into Phase 3 becomes realistic.

Some will say maybe, some will say no — but who really knows what goes on in the backrooms of big pharma. What’s clear is that one major player could be first to step up, fill the missing piece, and make the Trinity Approach stand out as a real cancer treatment. A buyout value north of $6/share isn’t unreasonable — maybe even better than a 5x gainer. But when it comes to spec — maybe some, maybe none, but not too much is a way we think here.

Another Spec: MOJO – As a footnote, Equator Beverage Company (MOJO) stock. Thinly traded, under-a-buck OTC issue tied to a no-frills, refreshing coconut water drink. They’ve reported positive earnings and even bought back stock. We keep a case or two here (and just a few shares) simply because we like it.

Spec stocks are viewed here as “maybe some or none” — not too much, just enough to keep it fun. Keep an eye on all your stocks, invest and trade according to your own game plan and appetite for risk, and always stay aware.

__


If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Monday, September 15, 2025

Jones Notes on Stocks to Watch

  


Market Talk 

Inflation remains sticky and tariffs add uncertainty, while the Fed is signaling concern about rising unemployment. That mix makes rate cuts likely, even as growth softens — the kind of backdrop that often fuels stagflation worries. In that environment, hard assets shine. Gold tends to outperform when inflation runs hot and stocks stumble, while silver, its high-beta cousin, often delivers sharper moves once the bid arrives.

On the equity side, gold and silver miners are still front and center — Kinross Gold (KGC) and Hecla Mining (HL) (scroll back to prior posts). Both have strengths in a world of growing demand, and both are benefiting from renewed interest in hard-asset exposure.

 Stock Talk

KGC and HL remain core mining names, but other materials deserve a look. Ramaco Resources (METCB) ties into the Brook Mine rare earths potential, (with a maybe some of the more volatile METC) while its high dividend preferred (METCI) pays investors to wait.

Meanwhile, in tech, Lam Research (LRCX), HPE, and Intel (INTC) all sit at the crossroads of semiconductors and AI build-outs — a sector still volatile but where equipment and infrastructure names have room to run as data-center demand expands.

Russian drones over Poland and now Romania are making the kinds of advanced systems that KTOS is developing here in the US more visible by those who pay attention.


Some Spec Stocks of Note:

Oncolytics Biotech (ONCY) has gained fresh visibility from the KRAS MSS update and growing awareness of the Trinity approach — the potential of Pela as the third leg alongside checkpoint inhibitors and targeted ADCs. Still, the near trading action looks deal-dependent, with a partner or buyout likely needed to escape the “old ways” of biotech drift.

What can’t be overlooked is that KRAS mutant MSS cancers span across many tumor types. Abnormal cell multiplication in KRAS cancers has long been one of the hardest challenges in oncology. That makes it difficult for Big Pharma to ignore.

A deal to bring Pelareorep into their fold — alongside checkpoint inhibitors and ADCs — seems very possible. Whether that happens soon may hinge both on escaping the old patterns that weigh down small-cap biotech and on the new CEO’s mission-driven push to get a deal done.

Opendoor (OPEN), while risky and shorted, has shown how new management with bold ideas — and lower rates — can spark both investors and meme-style bursts. A theme that could persist if the Fed eases further.

And as a footnote — Equator Beverage Company (MOJO) stock. Thinly traded, under-a-buck OTC issue tied to a no-frills, refreshing coconut water drink. They’ve reported positive earnings and even bought back stock. We keep a case or two here (and just a few shares) simply because we like it.

Spec stocks are viewed here as “maybe some or none” — not too much, just enough to keep it fun. Keep an eye on all your stocks, invest and trade according to your own game plan and appetite for risk, and always stay aware.

__


If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Tuesday, September 9, 2025

The Trinity: The Missing Puzzle Piece to Fight Cancer — Update: Watch ONCY

  


Part 2:  The Trinity Approach 

New colorectal results — backed by pancreatic and breast cancer signals — show how Pela may be the missing piece that makes checkpoint inhibitors finally work where they’ve fallen short.

Top Line – Quick Read

ONCY’s new colorectal data may be exploratory, but the impact is hard to miss. KRAS-mutant MSS colorectal cancer is one of the toughest oncology populations, making up roughly 35–40% of all colorectal cases — about 50–60,000 patients every year in the U.S. and nearly 700,000 worldwide. Using just checkpoint inhibitors has fallen short here without the immune agent that Pela fits into like the missing puzzle piece. Pela changes that equation: flipping tumors from cold to hot, opening the door for checkpoint inhibitors to finally work. Seeing PFS nearly tripled and OS more than doubled isn’t just numbers — it signals improved and longer life, and within the Trinity framework — CI, ADC, and Pela — perhaps even the possibility of durable remission, or even a cure...

The Trinity Mechanisms Explained

Yesterday’s PR on new colorectal (KRAS-mutant MSS) results adds weight to the Trinity Approach, alongside earlier pancreatic cancer signals and supportive breast cancer data. We’ve been tracking this framework — three mechanisms that big pharma could already be sketching on their planning boards, waiting for more validation. Here’s how each part works, and why today’s data matters:

  • Checkpoint Inhibitors (CI): block certain proteins (like PD-1) that tumors use as a shield to suppress the T-cell attack. This opens the doors for Pela to attack.

  • Antibody–Drug Conjugates (ADCs): deliver precision-targeted antibody and chemo payloads, less harshly than traditional chemotherapy.

  • Pelareorep (Pela): infiltrates cold tumors, replicates inside cancer cells, and triggers their death. At the same time, it flips the immune switch — multiplying T-fight cells, building memory T-cells, and turning the tumor from invisible to inflamed. This priming effect is what makes checkpoint inhibitors and ADCs hit harder.

The new colorectal results just announced add more validation that Pela has something real.

Stock Talk – Combo Power

As we outlined in the last report, the Trinity isn’t just three lanes running parallel — it’s about the combos:

  • CI + Pela: immune shields removed, tumors primed, stronger immune attack.

  • ADC + Pela: payloads delivered into tumors already sensitized, hitting harder with less collateral damage.

  • CI + ADC + Pela: the full integration — immune priming, checkpoint release, and precision kill.

What’s different now is that Pela’s role just got more validated with the new colorectal results just announced. That shifts it from “hypothetical partner” to “credible force multiplier” for the big pharma players we already highlighted.

Investor Lens – Odds Reset

The new colorectal data just announced comes from a subgroup exploratory trial, so it isn’t the final word. But even at this stage, seeing PFS nearly tripled and OS more than doubled is a signal with potentially huge impact — especially in a population where using just checkpoint inhibitors has fallen short without the immune agent that Pela fits into like the missing puzzle piece.

That moves Pela up a notch. For investors, the angle isn’t ONCY proving it can stand alone — it’s that the data raises the odds of buyout or partner interest from big pharma. ONCY now carries somewhat less speculative risk with potential upside, possibly significant if the stars line up.

It remains a “maybe” — to see if ONCY management can maximize potential or languish in the old-guard ways of the past.

Why the New Colorectal Results Matter

KRAS-mutant MSS colorectal cancer is one of the hardest-to-treat groups in oncology. Roughly 40–45% of all colorectal cancers are KRAS-mutant, and most of those are MSS. That works out to about 35–40% of all CRC cases — or 50,000–60,000 new patients every year in the U.S. and ~700,000 worldwide. Using just checkpoint inhibitors has fallen short here without the immune agent that Pela fits into like the missing puzzle piece.

Pela changes that equation. By flipping tumors from cold to hot, Pela can make checkpoint inhibitors work in this population for the first time. That’s why PFS nearly tripling and OS more than doubling isn’t just numbers — it’s impact. It is not hyperbole to say the potential is improved and longer life, and within the Trinity framework — CI, ADC, and Pela — maybe even the chance for durable remission, or even a cure.

The new data makes ONCY’s Pelareorep harder to ignore — and seems to put ONCY at square one directly on center stage.  Large pharma is on the hunt for missing pieces that fit into current regimens safely — and Pelareorep now looks more like one that may deliver relative safety and synergistic effectiveness.


___

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare !

For now, we close by noting that any view on the market and stocks on any particular day may change in the future days to come. That is why we watch and see how our views match up with the reality of the time.  But trying to look ahead a few months into the future may be a way to do things.  If you think too deep about world events and the recent alliances forming, projecting ahead can be a dicey endeavor.  In all -  we use the word maybe "some", not "too much" and play it accordingly.  Remember, never get arrogant in our various notions because things do change in the market and individual stocks are subject to many factors outside of our control.. So we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________